-
Personal view:
#CARTcell product performance in#haematological#malignancies before and after marketing authorisationhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30729-6/fulltext … -
Improving
#CARTcell therapy for#cancer by regulating 2#proteins https://buff.ly/2GMiRKT@FierceBiotechpic.twitter.com/I4k5Pe3NgO
-
Hear expert insight and practical strategies for appropriately integrating
#CARTcell therapy into treatment plans for patients with leukemia and lymphoma: Join us at#TCTM20 in Orlando on February 20th for a MasterClass symposium.http://bit.ly/CART20 -
@BPI_TechEditor overviews the challenges that remain in developing and manufacturing#CARTcell therapies in the introduction to BPI's latest Featured Report. Check out her synopsis as well as interviews with key industry players here: http://ow.ly/WCVC50ycqXf pic.twitter.com/1NoTE7VcZV
-
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the EBMT and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
#CARTcell@i_yakoub_aghahttp://www.haematologica.org/content/105/2/297 … -
#CARTcell therapy has emerged as a new avenue of treatment for heavily pretreated patients with relapsed/refractory#lymphoma@UTSWNewshttp://ow.ly/VTUS50yaCJ3 -
Targeting
#CML stem cells with#CARTcell. >>>#CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells#leusmhttps://cancerres.aacrjournals.org/content/early/2018/12/04/0008-5472.CAN-18-1078 … -
#UPenn scientists receive#ACGT grant to accelerate#CARTCell clinical trial https://www.1stoncology.com/blog/upenn-scientists-receive-acgt-grant-to-accelerate-car-t-cell-clinical-trial1234553699 … -
~30-minute
#MedscapeEdu video on the appropriate use of#CARTcell therapy in hematologic malignancies. [WATCH]: http://ms.spr.ly/6016TZYlw --- -w/ Dr. Sattva Neelapu of@MDAndersonNews & other expertspic.twitter.com/ARbDqcKOVI
-
#CARTcell Products Among Top Advances in Non-Hodgkin Lymphoma#lymphoma@UTSWNews http://ow.ly/Qlk150yaxce -
The application is supported by findings from the phase II ZUMA-2 trial, in which a single infusion of the
#CARTcell therapy led to an overall response rate of 93%, including a 67% complete response rate, in this patient population#MCL#lymphomahttp://ow.ly/vAIP50y8u0C -
Looks like a very useful article on the development of
#CARTcell therapies with a focus on the challenges encountered navigating the regulatory process in Europe and an update on their performance after approval. https://twitter.com/abouelem/status/1223212072122626048 …
-

#CART2020: Day 2 of the#EHA-#EBMT 2nd European CAR T Cell Meeting kicks off with a full auditorium in Sitges, Spain! The first keynote of the day was an insightful presentation by Prof Carl June on the latest updates in#cartcell therapy.#celltherapypic.twitter.com/TyQUGMaJyB
-
Latest: tisagenlecleucel (Kymriah) will be available for adults with R/R DLCBL
#lymphoma#CARTcell https://thelimbic.com/haematology/car-t-cell-therapy-access-expands-to-dlbcl-patients-as-local-manufacture-starts/ …@PeterMacCC@GregHuntMP -
#BMT#CellTherapy#CARTcell people,
is our 





team that keeps @ASTCT




https://twitter.com/astct/status/1222987232392491014 …
-
Dr. Deepu Madduri
@IcahnMountSinai presents today at the 2nd European#CARTCell Meeting in Spain,@TheEBMT https://www.ebmt.org/events/2nd-european-car-t-cell-meeting … https://www.mountsinai.org/profiles/deepu-madduri …pic.twitter.com/M92VOSZoe8
-
Caron Jacobson, MD and colleagues have identified these important factors that physicians should consider when evaluating patients for commercial CAR T-cell therapy.
#CARTcell,#lymphoma https://www.dana-farber.org/for-physicians/clinical-resources/hematologic-malignancies-resources/advances-in-hematologic-malignancies-newsletter/issue-11-fall-2019/car-t-cells-off-trial/?utm_source=Twitter&utm_medium=social&utm_campaign=HMEnewsfall19 … -
Penn researchers identify cancer cell defect driving resistance to
#CARTcell therapy – https://www.eurekalert.org/pub_releases/2020-01/uops-pri012820.php … -
What about $SRNE’s CD38
#CARTcell program and/or the CEA CAR program it ripped off of my company? Have they disclosed the RV packaging plasmid issue on the CEA program yet? Spoiler: no. They have no business taking on any new programs, and they certainly aren’t virologists!Prikaži ovu nit -
Packed house at the EBMT CAR-T cell meeting in Spain.
#CART2020#CARTcell. pic.twitter.com/w7N5SjTaDr
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.